Cargando…

Clinical outcomes of low-dose-rate brachytherapy based radiotherapy for intermediate risk prostate cancer

PURPOSE: To monitor the outcomes for intermediate-risk prostate cancer patients treated with biologically effective dose (BED) ≥ 200 Gy radiotherapy using low-dose-rate (LDR) brachytherapy. MATERIAL AND METHODS: Between 2005 and 2016, a total of 397 patients with intermediate-risk prostate cancer we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okamoto, Keisei, Okuyama, Kahori, Kohno, Naoaki, Tsugawa, Takuya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2020
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073334/ https://www.ncbi.nlm.nih.gov/pubmed/32190064 http://dx.doi.org/10.5114/jcb.2020.92405

Ejemplares similares

High biologically effective dose radiation therapy using brachytherapy in combination with external beam radiotherapy for high-risk prostate cancer
por: Okamoto, Keisei, et al.
Publicado: (2017)

Ten‐step method of high‐dose LDR (125)I brachytherapy for intermediate‐risk prostate cancer
por: Okamoto, Keisei
Publicado: (2021)

Prostate cancer with nodular bladder invasion (stage T4N1) cured by low-dose-rate brachytherapy with seminal vesicle implantation in combination with external beam radiotherapy of biologically effective dose ≥ 220 Gy: a case report
por: Okamoto, Keisei
Publicado: (2021)

After low and high dose-rate interstitial brachytherapy followed by IMRT radiotherapy for intermediate and high risk prostate cancer
por: Nakamura, Satoshi, et al.
Publicado: (2016)

Focal low-dose-rate prostate brachytherapy for low- and intermediate-risk prostate cancer
por: Kunogi, Hiroaki, et al.
Publicado: (2020)

Comparative effectiveness of low-dose-rate brachytherapy with or without external beam radiotherapy in favorable and unfavorable intermediate-risk prostate cancer
por: Tsumura, Hideyasu, et al.
Publicado: (2022)

Very high-risk locally advanced prostate ductal adenocarcinoma cured using low-dose-rate brachytherapy, with seminal vesicle implantation in combination with external beam radiotherapy at a biologically effective dose ≥ 220 Gy: two case reports with a long-term follow-up
por: Okamoto, Keisei
Publicado: (2022)

High-dose-rate brachytherapy with external beam radiotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer
por: Yamazaki, Hideya, et al.
Publicado: (2021)

A comparison of outcomes for patients with intermediate and high risk prostate cancer treated with low dose rate and high dose rate brachytherapy in combination with external beam radiotherapy
por: Slevin, Finbar, et al.
Publicado: (2019)

Low dose rate prostate brachytherapy
por: Stish, Bradley J., et al.
Publicado: (2018)

Focal low dose-rate brachytherapy for low to intermediate risk prostate cancer: preliminary experience at an Australian institution
por: Anderson, Elliot, et al.
Publicado: (2021)

Definitions of “Cure” After Low-Dose-Rate Brachytherapy in Low- and Intermediate-Risk Prostate Cancer: Phoenix or Surgical?
por: Boehle, Andreas, et al.
Publicado: (2022)

Do androgen deprivation and the biologically equivalent dose matter in low‐dose‐rate brachytherapy for intermediate‐risk prostate cancer?
por: Tabata, Ryuji, et al.
Publicado: (2016)

Ablative Radiotherapy in Prostate Cancer: Stereotactic Body Radiotherapy and High Dose Rate Brachytherapy
por: Ma, Ting Martin, et al.
Publicado: (2020)

The oncologic and safety outcomes of low-dose-rate brachytherapy for the treatment of prostate cancer
por: Tanaka, Nobumichi
Publicado: (2023)

High-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer: long-term experience of Swedish single-center
por: Johansson, Bengt, et al.
Publicado: (2021)

Salvage low-dose-rate (125)I partial prostate brachytherapy after dose-escalated external beam radiotherapy
por: Chang, Lynn, et al.
Publicado: (2014)

Direct comparison of low-dose-rate brachytherapy versus radical prostatectomy using the surgical definition of biochemical recurrence for patients with intermediate-risk prostate cancer
por: Tsumura, Hideyasu, et al.
Publicado: (2022)

Focal low-dose rate brachytherapy for the treatment of prostate cancer
por: Tong, William Y, et al.
Publicado: (2013)

Excessive waitlists and delays to treatment with low-dose-rate brachytherapy predict an increased risk of recurrence and metastases in intermediate-risk prostatic carcinoma
por: Khanolkar, Rutvij A., et al.
Publicado: (2021)

High-Dose-Rate Brachytherapy as Monotherapy for Low- and Intermediate-Risk Prostate Cancer. Oncological Outcomes After a Median 15-Year Follow-Up
por: Behmueller, Manuel, et al.
Publicado: (2021)

Low-/high-dose-rate brachytherapy boost in patients with intermediate-risk prostate cancer treated with radiotherapy: long-term results from a single institution team experience
por: Villalba, Silvia Rodríguez, et al.
Publicado: (2021)

Low-dose-rate or high-dose-rate brachytherapy in treatment of prostate cancer – between options
por: Skowronek, Janusz
Publicado: (2013)

Treatment patterns of high-dose-rate and low-dose-rate brachytherapy as monotherapy for prostate cancer
por: Barnes, Justin, et al.
Publicado: (2019)

Single fraction high-dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: toxicities and early outcomes from a single institutional experience
por: Barnes, Justin M., et al.
Publicado: (2019)

A novel perineal shield for low-dose-rate prostate brachytherapy
por: Weiner, Joseph P., et al.
Publicado: (2015)

Improving rectal dosimetry for patients with intermediate and high-risk prostate cancer undergoing combined high-dose-rate brachytherapy and external beam radiotherapy with hydrogel space
por: Chao, Michael, et al.
Publicado: (2019)

The direct prognosis comparison of (125)I low-dose-rate brachytherapy versus laparoscopic radical prostatectomy for patients with intermediate-risk prostate cancer
por: Liang, Zhen, et al.
Publicado: (2023)

Comparison of Image-Guided Intensity-Modulated Radiotherapy and Low-dose Rate Brachytherapy with or without External Beam Radiotherapy in Patients with Localized Prostate Cancer
por: Tsubokura, Takuji, et al.
Publicado: (2018)

High-dose-rate brachytherapy boost for elderly patients with intermediate to high-risk prostate cancer: 5-year clinical outcome of the PROSTAGE cohort
por: Marotte, Delphine, et al.
Publicado: (2022)

Radiotherapy for Clinically Localized T3b or T4 Very-High-Risk Prostate Cancer-Role of Dose Escalation Using High-Dose-Rate Brachytherapy Boost or High Dose Intensity Modulated Radiotherapy
por: Yamazaki, Hideya, et al.
Publicado: (2021)

Pulmonary Metastases After Low-Dose-Rate Brachytherapy for Localized Prostate Cancer
por: Kido, Masahito, et al.
Publicado: (2014)

Control charts for evaluation of quality of low-dose-rate brachytherapy for prostate cancer
por: Nasser, Nicola J., et al.
Publicado: (2022)

Unexpected lower biochemical control of high-dose-rate brachytherapy boost than low-dose-rate brachytherapy boost for clinically localized prostate cancer
por: Yamazaki, Hideya, et al.
Publicado: (2020)

A Phase 2 Randomized Pilot Study Comparing High-Dose-Rate Brachytherapy and Low-Dose-Rate Brachytherapy as Monotherapy in Localized Prostate Cancer
por: Hathout, Lara, et al.
Publicado: (2019)

High dose-rate brachytherapy in the treatment of prostate cancer
por: Mendez, Lucas C., et al.
Publicado: (2018)

Dose Distribution of High Dose-Rate and Low Dose-Rate Prostate Brachytherapy at Different Intervals—Impact of a Hydrogel Spacer and Prostate Volume
por: Haddad, Hathal, et al.
Publicado: (2023)

High-dose-rate brachytherapy delivered in two fractions as monotherapy for low-risk prostate cancer
por: Cendales, Ricardo, et al.
Publicado: (2015)

A Brief Review of Low-Dose Rate (LDR) and High-Dose Rate (HDR) Brachytherapy Boost for High-Risk Prostate
por: Fischer-Valuck, Benjamin W., et al.
Publicado: (2019)

Conventional dose versus dose escalated radiotherapy including high-dose-rate brachytherapy boost for patients with Gleason score 9–10 clinical localized prostate cancer
por: Yamazaki, Hideya, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2rpnol5it4o94mk0r4i0oeeldk